Targeted drug delivery systems for elemene in cancer therapy: The story thus far

• Published in: Biomedicine & pharmacotherapy 2023-10, Vol.166, p.115331-115331, Article 115331
• Main Authors: Tian, Huan, Zhao, Feng, Qi, Qing-rui, Yue, Bao-sen, Zhai, Bing-tao
• Format: Article
• Language: English
• Subjects: Active targeting; Codelivery system; Elemene; Passive targeting; Stimuli-responsive targeting; Targeted drug delivery system; β-Elemene
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115331

Elemene (ELE) is a group of broad-spectrum anticancer active ingredients with low toxicity extracted from traditional Chinese medicines (TCMs), such as Curcumae Rhizoma and Curcuma Radix, which can exert antitumour activities by regulating various signal pathways and targets. However, the strong hydrophobicity, short half-life, low bioavailability and weak in vivo targeting ability of ELE restrict its use. Targeted drug delivery systems based on nanomaterials are among the most viable methods to overcome these shortcomings. In this review, we first summarize recent studies on the clinical uses of ELE as an adjunct antitumour drug. ELE-based combination strategies have great promise for enhancing efficacy, reducing adverse reactions, and improving patients' quality of life and immune function. Second, we summarize recent studies on the antitumour mechanisms of ELE and ELE-based combination strategies. The potential mechanisms include inducing pyroptosis and ferroptosis, promoting senescence, regulating METTL3-mediated m6A modification, suppressing the Warburg effect, and inducing apoptosis and cell cycle arrest. Most importantly, we comprehensively summarize studies on the combination of targeted drug delivery systems with ELE, including passively and actively targeted drug delivery systems, stimuli-responsive drug delivery systems, and codelivery systems for ELE combined with other therapies, which have great promise in improving drug bioavailability, increasing drug targeting ability, controlling drug release, enhancing drug efficacy, reducing drug adverse effects and reversing MDR. Our summary will provide a reference for the combination of TCMs such as ELE with advanced targeted drug delivery systems in the future. [Display omitted] •Elemene is a useful adjunct drug in clinical treatment of mid-advanced stage tumours.•Elemene and elemene-based combination strategies exert effects by multiple targets.•Passively and actively targeted drug delivery systems for elemene.•Stimuli-responsive drug delivery systems for elemene.•Codelivery systems for elemene combined with other therapies.